Related Experiment Video
Updated: Nov 3, 2025
Treatment of Osteochondral Defects in the Rabbit's Knee Joint by Implantation of Allogeneic Mesenchymal Stem Cells in Fibrin Clots
Published on: May 21, 2013
Advantages and Disadvantages of Different Treatment Methods in Achondroplasia: A Review
Wiktoria Wrobel1, Emilia Pach1, Iwona Ben-Skowronek1
1Metabolic Laboratory, Department of Paediatric Endocrinology and Diabetology with Endocrine, Medical University in Lublin, Prof. A. Gebala Street 6, 20-093 Lublin, Poland.
Insights
Achondroplasia treatments are reviewed, focusing on drugs targeting FGFR3 gene mutations. Current options like growth hormone and future therapies such as vosoritide show promise for improving patient quality of life.
Area of Science:
- Genetics and Molecular Biology
- Endocrinology and Metabolism
- Pharmacology and Therapeutics
Background:
- Achondroplasia (ACH) is a genetic disorder caused by a missense mutation in the FGFR3 gene, leading to short stature and potential orthopedic/neurological complications.
- Current management of ACH primarily involves surgical interventions, which are invasive and address complications rather than the underlying condition.
- There is an urgent need for effective pharmacological treatments to manage ACH symptoms and improve patients' quality of life.
Purpose of the Study:
- To review current and potential pharmacological treatments for achondroplasia.
- To evaluate the advantages and disadvantages of drugs in various clinical trial stages.
- To assess the impact of potential treatments on ACH symptoms beyond short stature, including spinal stenosis and body proportionality.
Main Methods:
- Systematic review of human and animal studies on pharmacological interventions for achondroplasia.
- Analysis of clinical trial data for drugs targeting FGFR3-related pathways.
- Evaluation of treatment effects on skeletal growth, spinal canal stenosis, foramen magnum narrowing, and overall body structure.
Main Results:
- Recombinant human growth hormone (rhGH) currently shows the most promise among available treatments.
- Vosoritide is a potential future therapy demonstrating significant promise in clinical trials.
- Other drug candidates are in early-stage development, with varying efficacy and safety profiles.
Conclusions:
- Pharmacological treatments offer a promising alternative to surgery for managing achondroplasia.
- Targeting FGFR3 signaling pathways can address multiple facets of ACH, improving patient outcomes and quality of life.
- Continued research and clinical trials are essential to advance the development of effective achondroplasia therapies.
Abstract:
Achondroplasia (ACH) is a disease caused by a missense mutation in the FGFR3 (fibroblast growth factor receptor 3) gene, which is the most common cause of short stature in humans. The treatment of ACH is necessary and urgent because untreated achondroplasia has many complications, both orthopedic and neurological, which ultimately lead to disability. This review presents the current and potential pharmacological treatments for achondroplasia, highlighting the advantages and disadvantages of all the drugs that have been demonstrated in human and animal studies in different stages of clinical trials. The article includes the potential impacts of drugs on achondroplasia symptoms other than short stature, including their effects on spinal canal stenosis, the narrowing of the foramen magnum and the proportionality of body structure. Addressing these effects could significantly improve the quality of life of patients, possibly reducing the frequency and necessity of hospitalization and painful surgical procedures, which are currently the only therapeutic options used. The criteria for a good drug for achondroplasia are best met by recombinant human growth hormone at present and will potentially be met by vosoritide in the future, while the rest of the drugs are in the early stages of clinical trials.
